US20160151380A1

US20160151380A1 - Therapies for diseases caused by arthropod-borne parasites

Info

Publication number: US20160151380A1
Application number: US14/904,686
Authority: US
Inventors: Shirley LUCKHART; Cecilia GIULIVI
Original assignee: University of California
Current assignee: University of California
Priority date: 2013-07-12
Filing date: 2014-07-11
Publication date: 2016-06-02
Also published as: US9918989B2; WO2015006752A1; WO2015006753A2; WO2015006753A3; US20160151379A1

Abstract

The present disclosure provides methods for treating or preventing diseases caused by arthropod-borne parasites by administration of a protein kinase inhibitor to a mammalian subject infected with or at risk of exposure to an arthropod-borne parasite. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in arthropods feeding on recipients of the regimens. Additionally, the present disclosure provides methods for screening candidate anti-parasitic agents.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/923,405, filed Jan. 3, 2014, and U.S. Provisional Application No. 61/845,920, filed Jul. 12, 2013, which are incorporated herein by reference in their entirety for all purposes.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government support under Grant Nos. AI073745 and AI080799, awarded by National Institutes of Health. The Government has certain rights in the invention.

FIELD

BACKGROUND

Chagas disease, also known as American trypanosomiasis, is a parasitic disease caused by Trypanosoma cruzi. T. cruzi is a protozoan parasite that is mainly transmitted by blood-feeding insects known as kissing bugs (triatomines) through their feces and contaminated objects, including food, and drink. The area where kissing bug species have been reported spans from the southern part of South America up to the Great Lakes in the northern part of the United States (Bern et al., N Engl J Med, 364:2527-2534, 2011).
Clinically Chagas disease is classified into acute and chronic phases. The acute phase begins when T. cruzi infiltrates the body and starts multiplying within different organs and tissues. The symptoms during the acute phase can be mild and nonspecific, including fever and swelling at the site of infection (e.g., swelling of the eyelid, also referred to as Romana's sign). However, in some instances, acute infection can cause severe inflammation of the heart or brain (myocarditis or meningoencephalitis) which can be deadly (Bern et al., supra, 2011). The spectrum of symptoms depends on factors such as the parasite burden and host immunocompetence. The acute phase lasts 4 to 8 weeks, after which initial symptoms cease, and the infection enters a lifelong chronic phase. In the chronic phase, intracellular T. cruzi amastigotes remain in infected tissues, especially in cardiac and skeletal muscle, but the parasitemia levels become undetectable by microscopy. Clinical symptoms of chronic Chagas disease can develop decades later in a significant number of chronically infected individuals. In this way, people unaware of their infection can unwittingly transmit the parasite via blood, tissue, and organ donations, as well as from mother to child. In about 30% of chronically-infected individuals Chagas disease develops into a life-threatening illness characterized by abnormal heart rhythms leading to an increased risk of sudden death, heart failure, and/or gastrointestinal disturbances.
According to the Centers for Disease Control (CDC), an estimated eight million people living in Mexico, Central and South America are infected. New figures on the prevalence of the disease in endemic countries combined with data on immigration suggests that about 300,000 immigrants in the United States are likely infected with T. cruzi. Thus, Chagas disease is a serious illness affecting a significant portion of the population.
Even though T. cruzi was first discovered a century ago, Chagas disease remains largely ignored. There are only two drugs used to treat acute-phase disease, benznidazole (since 1960s) and nifurtimox (since 1970s), both of which are impractical because of low efficacy and frequent side effects. Additionally, neither benznidazole nor nifurtimox is approved for use by the United States Food and Drug Administration (Bern et al., supra, 2011). Treatment of the chronic form of the disease is still limited to the management of symptoms (e.g., antiarrhythmics, steroids, pacemakers, etc.). Even heart transplantation cannot ensure a cure, because the parasites hidden within other organs will eventually reinvade the transplanted heart. Despite the well-recognized limitations of current therapeutic approaches and the general acceptance that specific treatment should be made available to infected individuals, new Chagas disease treatments have not reached the clinic. Moreover, T. cruzi like Plasmodium sp. (arthropod-borne parasite that causes malaria) changes rapidly, thus quickly acquiring resistance to current treatments. For this further reason and because there are no effective Chagas disease treatments that target T. cruzi when it resides within a host cell (see, e.g., Urbina, Acta Trop, 115:55-68, 2010), there is a need for an expanded drug arsenal for targeting T. cruzi at different stages in its life cycle.
The CDC has named Chagas disease as one of five (along with Neurocysticercosis, Toxocariasis, Toxoplasmosis, and Trichomoniasis) neglected parasite infections in the United States as public health priorities based on the severity of the illnesses, the number of people infected, and the ability to prevent and treat the disease. Thus, there remains a need for therapy regimens to treat or prevent other diseases caused by arthropod-borne parasites, which are safe and do not encourage development of drug-resistant parasites. In particular, new anti-Chagas disease drugs with an improved safety profile are urgently needed.

BRIEF SUMMARY

The present disclosure provides methods for treating or preventing diseases caused by arthropod-borne parasites by administration of a protein kinase inhibitor to a mammalian subject infected with or at risk of exposure to an arthropod-borne parasite. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in arthropods feeding on recipients of the regimens. Additionally, the present disclosure provides methods for screening candidate anti-parasitic agents.
In one aspect, the present disclosure provides methods for treating or preventing a parasitic disease caused by an arthropod-borne parasite by administering a protein kinase inhibitor to a mammalian subject infected with or at risk of exposure to the arthropod-borne parasite (e.g., a mammalian subject in need thereof) under conditions effective for treating or preventing the parasitic disease. In some embodiments, the arthropod-borne parasite is a protozon parasite. In some embodiments, the present disclosure provides methods for treating or preventing a disease caused by a protozoan parasite comprising: administering a first protein kinase inhibitor and a second protein kinase inhibitor to a mammalian subject in need thereof under conditions effective for treating or preventing the disease caused by the protozoan parasite. The present disclosure also provides methods for treating or preventing a disease caused by a protozoan parasite comprising: administering a protein kinase inhibitor and an additional antiprotozoan drug to a mammalian subject in need thereof under conditions effective for treating or preventing the disease caused by the protozoan parasite. In some embodiments, the administering reduces activity of at least one mammalian protein kinase. In some embodiments, the protein kinase inhibitor comprises a first and a second protein kinase inhibitor. In some preferred embodiments, the protozoan parasite is an arthropod-borne parasite selected from the group consisting of Plasmodium sp., Leishmania sp., Babesia sp., and Trypanosoma sp. In some embodiments, the parasitic disease is not malaria and the parasite is not a species of Plasmodium. In some embodiments, the protein kinase inhibitor reduces activity of an arthropod kinase. In some embodiments, the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a c-Jun N-terminal kinase (JNK) family, and a p38 mitogen activated protein kinase (MAPK) family. In some embodiments, the subject is infected with a protozoan parasite. In some embodiments, the subject is infected with a drug-resistant protozoan parasite (e.g., resistant to currently used anti-parasitic drugs). In some embodiments, the subject is acutely infected with a protozoan parasite, while in other embodiments the subject is chronically infected with a protozoan parasite. In some embodiments, the subject is experiencing a symptom of the disease prior to the administering step. In some embodiments, treating the disease comprises alleviating a symptom of the disease experienced by the subject. In some embodiments, the subject is an uninfected individual planning to visit a disease endemic area after (6 hours-72 hours, 1, to or 3 days) the administering step. That is the individual is not infected with but likely to be exposed to a protozoan parasite. In some embodiments, the administering commences and concludes before the uninfected individual visits a parasitic disease endemic area. In other embodiments, the administering commences before the uninfected individual visits a parasitic disease endemic area, and continues during the duration of their visit. That is in some embodiments, the administering concludes sometime after the uninfected individual leaves the parasitic disease endemic area (e.g., within thirty days of after last potential exposure). In some embodiments, preventing the disease comprises protecting the subject from developing parasitemia during their visit to the endemic area for a period of up to thirty days (between 0 and 30 days). In some embodiments, drug-resistant protozoan parasites (e.g., resistant to currently used anti-parasitic drugs) are known to be present in the disease endemic area.
Specifically, the present disclosure provides methods for treating or preventing Chagas disease comprising: administering a mammalian protein kinase inhibitor to a mammalian subject in need thereof under conditions effective for treating or preventing Chagas disease. In some embodiments, the mammalian protein kinase inhibitor comprises a first kinase inhibitor and a second kinase inhibitor, and the administering reduces activity of a first mammalian protein kinase and a second mammalian protein kinase. In some embodiments, the mammalian protein kinase comprises a member of a protein kinase C (PKC) family, a member of the protein kinase B (PKB) family, and/or a member of the phosphoinositide 3-kinase (PI3K) family. In some embodiments, the mammalian protein kinase inhibitor is capable of reducing activity of a Triatominae insect kinase. In some embodiments, the methods further comprise administering an effective amount of a further mammalian enzyme inhibitor to the mammalian subject. In some embodiments, the subject is infected with Trypanosoma cruzi. In some embodiments, the subject is acutely infected with T. cruzi, while in other embodiments the subject is chronically infected with T. cruzi. In some preferred embodiments, treating Chagas disease comprises alleviating a symptom of Chagas disease experienced by the subject. In some embodiments, the methods further comprise administering an effective amount of an additional antiparasitic agent to the mammalian subject. In some embodiments, the additional antiparasitic agent comprises one or both of benznidazole and nifurtimox. In some embodiments, the subject is an uninfected individual planning to visit a Chagas disease endemic area (e.g., Mexico, Central America or South America) after the administering step. That is the individual is not infected with but likely to be exposed to T. cruzi. In some embodiments, the administering commences and concludes before the uninfected individual visits a Chagas disease endemic area. In other embodiments, the administering commences before the uninfected individual visits a Chagas disease endemic area, and continues during the duration of their visit. That is in some embodiments, the administering concludes sometime after the uninfected individual leaves the Chagas disease endemic area (e.g., within thirty days of after last potential exposure). In some embodiments, preventing Chagas disease comprises protecting the subject from developing parasitemia during their visit to the endemic area for a period of up to thirty days. Generally, the present disclosure provides method for treating or preventing Chagas disease comprising: administering a protein kinase inhibitor to a subject infected with Trypanosoma cruzi under conditions effective for treating or preventing Chagas disease. Likewise, the present disclosure provides methods for treating or preventing a parasitic disease comprising: administering a protein kinase inhibitor to a subject infected with an arthropod-borne parasite under conditions effective for treating or preventing a parasitic disease.
Furthermore, the present disclosure provides methods of reducing transmission of Trypanosoma cruzi by a Triatominae vector, comprising administering a protein kinase inhibitor to a mammalian subject infected with Trypanosoma cruzi. under conditions effective for reducing transmission of the Trypanosoma cruzi ingested by the Triatominae vector in the subject's blood. The present disclosure also provides methods of reducing transmission of Trypanosoma cruzi by a Triatominae vector, comprising providing a bloodmeal comprising erythrocytes infected with Trypanosoma cruzi to a Triatominae vector in the presence of an effective amount of a protein kinase inhibitor for reducing transmission of the Trypanosoma cruzi ingested by the Triatominae vector in the bloodmeal. In some embodiments, the methods further comprise administering an additional anti-parasitic drug to the mammalian subject. In some embodiments, the bloodmeal is provided to the Triatominae vector in the further presence of an additional antiparasitic drug. In some embodiments, the protein kinase inhibitor comprises a first and a second protein kinase inhibitor. In some embodiments, the protein kinase inhibitor reduces activity of at least one mammalian protein kinase. In some embodiments, the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a c-Jun N-terminal kinase (JNK) family, and a p38 mitogen activated protein kinase (MAPK) family. In some preferred embodiments, the protein kinase inhibitor reduces activity of a Triatominae kinase. In some embodiments, the Triatominae kinase comprises one or more of the group consisting of cPKC, nPKC-delta, nPKC-epsilon, aPKC-zeta, PKD, PKN, JNK isoforms, and p38 MAPK isoforms. In some embodiments, the Triatominae kinase comprises aPKC-zeta. In some embodiments, the subject is infected with Trypanosoma cruzi. In some embodiments, the additional anti-parasitic drug comprises a one or both of benznidazole and nifurtimox.
The present disclosure also provides methods of identifying an antiparasitic compound, comprising: measuring activity of a mammalian or insect protein kinase in the presence and absence of a test compound; and identifying the test compound as an antiparasitic compound when the activity of the protein kinase is reduced in the presence as compared to the absence of the test compound. In some embodiments, the methods further comprise growing insect cells in vitro in the presence and absence of the test compound and identifying the test compound as insect-cell safe when viability or doubling time of the insect cells is not significantly reduced in the presence as compared to the absence of the test compound. In some embodiments, the mammalian protein kinase is a human protein kinase. In some embodiments, the human protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a c-Jun N-terminal kinase (JNK) family, and a p38 mitogen activated protein kinase (MAPK) family. In some embodiments, the methods are suitable for identifying an anti-Chagas disease compound. In such embodiments, the insect protein kinase is a Triatominae protein kinase, and the insect cells are Triatominae cells. In some embodiments, the Triatominae kinase comprises one or more of the group consisting of cPKC, nPKC-delta, nPKC-epsilon, aPKC-zeta, PKD, PKN, JNK isoforms and p38 MAPK isoforms. In some embodiments, the Triatominae kinase comprises aPKC-zeta. In some embodiments, the Triatominae cells are Rhodnius sp. cells (e.g., Rhodnius prolixus cells). The present disclosure also provides methods of identifying an anti-Chagas disease compound, comprising: comparing development of parasites in Triatominae vector after consumption of a bloodmeal comprising Trypanosoma cruzi in the presence and absence of a test compound; and identifying the test compound as an anti-Chagas disease compound when the development of parasites is reduced in the Triatominae vector in the presence as compared to the absence of the test compound.
Additionally the present disclosure provides pharmaceutical compositions comprising a first protein kinase inhibitor, a second protein kinase inhibitor, and one or both of a pharmaceutically acceptable excipient and carrier, wherein the kinase inhibitors are present in amounts effective to treat or prevent Chagas disease in a mammalian subject. In further embodiments, the present disclosure provides pharmaceutical compositions comprising a protein kinase inhibitor, an additional antiparasitic agent, and one or both of a pharmaceutically acceptable excipient and carrier, wherein the kinase inhibitor and the additional antiparasitic agent are present in amounts effective to treat or prevent Chagas disease in a mammalian subject. In still further embodiments, the present disclosure provides pharmaceutical compositions comprising: a protein kinase inhibitor attached to a mitochondrial-targeting moiety, and one or both of a pharmaceutically acceptable excipient and carrier, wherein the protein kinase inhibitor is present in an amount effective to treat or prevent Chagas disease in a mammalian subject.
The present disclosure provides methods for treating or preventing an arthropod-borne parasitic disease comprising: administering a mammalian protein kinase inhibitor to a mammalian subject in need thereof under conditions effective for treating or preventing the arthropod-borne parasitic disease, wherein the parasitic disease is not malaria. In some embodiments, the mammalian protein kinase inhibitor comprises a first kinase inhibitor and a second kinase inhibitor, and the administering reduces activity of a first mammalian protein kinase and a second mammalian protein kinase. In some embodiments, the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a protein kinase B (PKB) family, and a phosphoinositide 3-kinase (PI3K) family. In some embodiments, the mammalian protein kinase inhibitor is capable of reducing activity of an arthropod kinase. In some embodiments, the methods further comprise administering an effective amount of a further mammalian enzyme inhibitor to the mammalian subject. In some embodiments, the subject is infected with an arthropod-borne parasite which is not a Plasmodium sp. parasite. In some embodiments, the subject is acutely infected with the arthropod-borne parasite, while in other embodiments, the subject is chronically infected with the arthropod-borne parasite. In some embodiments, treating the parasitic disease comprises alleviating a symptom of the parasitic disease experienced by the subject. In some embodiments, the methods further comprise administering an effective amount of an additional antiparasitic agent to the mammalian subject. In some embodiments, the subject is an uninfected individual planning to visit a parasitic disease endemic area, and the administering step commences before the visit. In some embodiments, the subject is an uninfected individual planning to visit a parasitic disease endemic area, and the administering step concludes during or after the visit. In some embodiments, preventing the parasitic disease comprises protecting the subject from developing parasitemia during their visit to the endemic area for a period of up to thirty days.
Furthermore, the present disclosure provides methods of reducing transmission of an arthropod-borne parasite by an arthropod, comprising administering a protein kinase inhibitor to a mammalian subject infected with an arthropod-borne parasite under conditions effective for reducing transmission of the an arthropod-borne parasite ingested by the arthropod in the subject's blood. The present disclosure also provides methods of reducing transmission of an arthropod-borne parasite by an arthropod vector, comprising providing a bloodmeal comprising erythrocytes infected with an arthropod-borne parasite to an arthropod in the presence of an effective amount of a protein kinase inhibitor for reducing transmission of the an arthropod-borne parasite ingested by the arthropod in the bloodmeal. In some embodiments, the methods further comprise administering an additional anti-parasitic drug to the mammalian subject. In some embodiments, the bloodmeal is provided to the arthropod vector in the further presence of an additional antiparasitic drug. In some embodiments, the protein kinase inhibitor comprises a first and a second protein kinase inhibitor. In some embodiments, the protein kinase inhibitor reduces activity of at least one mammalian protein kinase. In some embodiments, the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a c-Jun N-terminal kinase (JNK) family, and a p38 mitogen activated protein kinase (MAPK) family. In some preferred embodiments, the protein kinase inhibitor reduces activity of an arthropod kinase. In some embodiments, the arthropod kinase comprises one or more of the group consisting of cPKC, nPKC-delta, nPKC-epsilon, aPKC-zeta, PKD, PKN, JNK isoforms, and p38 MAPK isoforms. In some embodiments, the arthropod kinase comprises aPKC-zeta. In some embodiments, the subject is infected with an arthropod-borne parasite. In some embodiments, the arthropod-borne parasite is not a species of Plasmodium and the arthropod is not a species of Anopheles.
Additionally, the present disclosure provides, methods of identifying an antiparasitic compound, comprising: measuring activity of a mammalian or insect protein kinase in the presence and absence of a test compound; and identifying the test compound as an antiparasitic compound when the activity of the protein kinase is reduced in the presence as compared to the absence of the test compound, and wherein the insect protein kinase is not a Anopheles sp. kinase. In some embodiments, the methods further comprise growing insect cells in vitro in the presence and absence of the test compound and identifying the test compound as insect-cell safe when viability or doubling time of the insect cells is not significantly reduced in the presence as compared to the absence of the test compound, and wherein the insect cells are not Anopheles sp. cells. In some embodiments, the mammalian protein kinase is a human protein kinase. In some embodiments, the insect protein kinase is selected from the group consisting of a sand-fly protein kinase, a tick protein kinase and a tsetse fly protein kinase.
Also provided by the present disclosure are pharmaceutical compositions comprising a first protein kinase inhibitor, a second protein kinase inhibitor, and one or both of a pharmaceutically acceptable excipient and carrier, wherein the kinase inhibitors are present in amounts effective to treat or prevent an arthropod-borne parasitic disease in a mammalian subject, wherein the parasitic disease is not malaria. In further embodiments, the present disclosure provides pharmaceutical compositions comprising a protein kinase inhibitor, an additional antiparasitic agent, and one or both of a pharmaceutically acceptable excipient and carrier, wherein the kinase inhibitor and the additional antiparasitic agent are present in amounts effective to treat or prevent an arthropod-borne parasitic disease in a mammalian subject, wherein the parasitic disease is not malaria. In still further embodiments, the present disclosure provides pharmaceutical compositions comprising: a protein kinase inhibitor attached to a mitochondrial-targeting moiety, and one or both of a pharmaceutically acceptable excipient and carrier, wherein the protein kinase inhibitor is present in an amount effective to treat or prevent an arthropod-borne parasitic disease in a mammalian subject, wherein the parasitic disease is not malaria. In some embodiments, the parasitic disease is selected from the group consisting of leishmaniasis, babesiosis, and African trypanosomiasis.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-C provides names and structures of exemplary protein kinase inhibitors.

FIG. 2A-2B shows that Anopheles stephensi p38 MAPK can be inhibited by SB203580 (SB) and BIRB 796, although neither inhibitor directly altered Plasmodium falciparum growth in vitro. In FIG. 2A, Anopheles stephensi ASE cells were pre-incubated with 10 μM SB203580 or 10 μM BIRB 796 and 2 h later stimulated with 1 μg/ml LPS. Phosphorylation of MK2, a downstream protein kinase substrate activated by p38 MAPK, was analyzed by western blot. Vehicle treatment was used as control group. Note that p-MK2 levels are undetectable in cells pre-treated with either inhibitor. In FIG. 2B, in vitro culture of P. falciparum was synchronized, treated with 1 μM or 10 μM SB203580 or 1 μM or 10 μM BIRB 796 for 48 h, then fixed and stained with propidium iodide. Parasitemia was determined by flow cytometry. Data were analyzed by Student's t-test (alpha=0.05) and are represented as mean±SEM, n=3. Neither inhibitor significantly altered parasite growth relative to the vehicle control.

FIG. 3A-3D shows that inhibition of p38 MAPK signaling reduced Plasmodium falciparum development in Anopheles stephensi. Briefly, 3-5 d old female A. stephensi were fed a bloodmeal with P. falciparum supplemented with SB203580, BIRB 796, or diluent control. Midguts were dissected and oocysts were counted at 10 days following infection. Dots in FIG. 3A and FIG. 3C represent oocyst numbers in one midgut, while percentage positive midguts or percentage of midguts with at least one oocyst are represented as means in FIG. 3B and FIG. 3D. Mean oocysts per midgut (lines, numbers on graph) were analyzed by ANOVA (alpha=0.05) for overall significance and by Student-Neuman-Keuls for pairwise comparisons using Graphpad Prism version 4.0 (San Diego, Calif.). Prevalences of mosquito infection (indicated on graph) were analyzed by chi-square (alpha=0.05). At 10 μM, SB203580 significantly reduced P. falciparum oocysts/midgut and infection prevalence in A. stephensi (*).

FIG. 4A-F shows that inhibition of Anopheles stephensi p38 MAPK in vivo increased midgut expression of anti-parasite genes. Briefly, 3-5 d old female A. stephensi were fed with killed lysate of P. falciparum supplemented with BIRB 796 or vehicle. Midgut samples were collected at 1-24 h post-feeding. Expression levels of anti-malarial genes at each time point were analyzed with quantitative PCR relative to the corresponding control group. Each dot represents the fold change in one repeat relative to control levels. Data were analyzed by Student's t-test (alpha=0.05), n=3-5. At 6 h post-feeding immune gene expression levels were significantly different from controls.

FIG. 5 shows that the midgut pJNK1/3 in A. stephensi is reduced after a P. falciparum-infected bloodmeal containing 10 μM SP600125, relative to controls. NB=no blood, B=blood, P=parasites, SP=SP600125.

FIG. 6A-D shows the prevalence (%) and intensity (mean oocysts/midgut) of P. falciparum infection in two separate cohorts of A. stephensi (n=50) is reduced after a P. falciparum-infected bloodmeal containing 10 μM SP600125, relative to controls.

FIG. 7 shows the fold change in midgut mRNA expression levels of complement-like immune factors (TEP1, APL1, LRIM1), a leucine-rich repeat gene (LRRD7), defensin (DEF), and nitric oxide synthase (NOS) following a bloodmeal containing 10 μM SP600125, relative to an untreated control bloodmeal (set at 1, dashed line). n=2 biological replicates.

DETAILED DESCRIPTION

The present disclosure provides methods for treating or preventing diseases caused by arthropod-borne parasites by administration of a protein kinase inhibitor, optionally with one or both of a further protein kinase inhibitor and an antiparasitic agent to a mammalian subject infected with or at risk of exposure to an arthropod-borne parasite. In some aspects, a protein kinase inhibitor is administered to the subject, while in other aspects a protein kinase inhibitor and one or both of a further protein kinase inhibitor and an antiparasitic agent are administered to the subject. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in arthropods feeding on recipients of the regimens (e.g., treated mammalian subjects). Additionally, the present disclosure provides methods for screening candidate anti-parasitic agents.
In one aspect, the present disclosure provides methods for treating or preventing Chagas disease by administration of a protein kinase inhibitor and optionally one or both of a further protein kinase inhibitor and an anti-Chagas disease agent to a mammalian subject infected with or at risk of exposure to Trypanosoma cruzi. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in Triatominae (e.g., kissing bugs) feeding on recipients of the regimens (e.g., treated mammalian subjects). Additionally, the present disclosure provides methods for screening candidate anti-Chagas disease agents.
Among the 140 triatomine species, Rhodnius prolixus—an important vector of Trypanosoma cruzi, the causative agent of Chagas' disease in Central and South America—has become a model for insect physiology and biochemistry. The genome of this species was recently targeted for sequencing, along with several organ-specific cDNA libraries including the midgut, the insect organ in which T. cruzi grows and develops. As such, R. prolixus, like Anopheles mosquitoes, can be targeted via ingested drugs from the mammalian host during bloodfeeding to inhibit parasite development. Critically, the midgut transcriptome of R. prolixus includes highly conserved proteins of the major signaling pathways initially determined to be of interest in the context of malaria, including the MAPKs (JNK, p38 MAPK), and the PKCs (see, e.g., Ribeiro et al., PLoS Neglected Tropical Diseases, 8: e2594, 2014).
The disclosure herein pertaining to malaria, Plasmodium sp. and mosquitoes is provided as an exemplary disclosure of embodiments that are applicable in general to diseases caused by arthropod-borne parasites. In particular, the disclosure herein pertaining to malaria, Plasmodium sp. and mosquitoes is also generally applicable to Chagas disease (American trypanosomiasis), Trypanosoma cruzi and Triatominae.

Kinase Inhibitors

PKC (protein kinase C) isoenzymes are an important family of serine/threonine protein kinases that contribute to many diverse cellular and tissue functions, as well as human disease pathologies including cancer development and progression (Bosco et al., Mini Rev Med Chem, 11:185-199, 2011; and Rosse et al., Nat Rev Mol Cell Biol, 11:103-112, 2010). The molecular architecture of PKC family members is conserved throughout the cPKC (classical PKC; cPKC α, cPKC β and cPKC γ), nPKC (novel PKC; nPKC δ, nPKC ε, nPKC η and nPKC θ) and aPKC (atypical PKC; a PKC ζ and aPKC ι) isoforms. All PKCs are comprised of a C-terminal serine/threonine protein kinase domain belonging to the AGC kinase (protein kinase A/protein kinase G/PKC family kinase) superfamily, and an N-terminal regulatory domain (Parker and Murray-Rust, J Cell Science, 117:131-132, 2004). The kinase domain has a C-terminal extension unique to AGC kinases that contains essential ‘priming’ phosphorylation sites required for catalytic activation (Pearce et al., Nat Rev Mol Cell Biol, 11:9-22, 2010), whereas in aPKCs, the most C-terminal of these is replaced by a phospho-mimetic Glu residue. The regulatory domain within all PKC isoforms has an inhibitory region (pseudo-substrate motif) and distinctive arrangements of C1, C2 and/or PB1 (Phox/Bem1) domains (the last being exclusive to the aPKCs) that together are crucial for conferring isoform-specific functions.
The aPKC isoforms (PKC ζ and PKC ι) diverge from other PKC family members as their regulatory domains are unresponsive to diacylglycerol, phosphatidylserine and Ca²⁺. Instead they are regulated by protein interactions, for example with polarity proteins Par-6, Par-3 and the Rho family GTPase cdc42 (Suzuki and Ohno, J Cell Sci, 119:979-987, 2003). aPKC has a role in establishing cell polarity and is required for normal cell proliferation, mitotic spindle orientation and migration.
There has been considerable interest in aPKCs as drug targets due to their roles in cancer development and progression (Fields and Regala, Pharmacol Res, 55:487-497, 2007). For example, PKC ζ is required for epidermal growth factor-induced migration of human breast and lung cancer cells and for colony-stimulating factor 1 chemotaxis of macrophages, among others. PKC ι promotes nicotine-induced migration and invasion of lung cancer cells via phosphorylation of calpains and is involved in other types of cancer. In addition, aPKC has been shown to interact with bona fide oncogenes, such as Ras and Notch in the fruit fly Drosophila melanogaster to promote an epithelial cell overgrowth that resembles cancer. Recent advances in malaria drug discovery have led to a proposal to use Plasmodium kinases as targets for next generation antimalarials (Zhang et al., Curr Top Med Chem, 12:456-472, 2012; Lin et al., PLoS One, 7, e49040, 2012; Lucet et al., Future Med Chem, 4:2295-2310, 2012; Aaberg et al., Biol Chem, 393:1121-1129, 2012; Biamonte at al., Bioorg Med Chem Lett, 23:2829-2843, 2013; Nag et al., Curr Drug Discovery Technol, 10:85-91, 2013; and Ochocki and Distefano, Med Chem Commm, 4:476-492, 2009). These reports, however, failed to consider manipulating kinase signalling pathways in the human or mosquito hosts to reduce parasitemia and block transmission.
Like many protein kinases, aPKC isoenzymes can be inhibited by small-molecule chemicals either through their ATP-binding or allosteric pockets (Knight and Shokat, Chem Biol, 12:621-637, 2005). Only a few selective chemical biology tools inhibit aPKC catalytic activity. These few catalytic inhibitors include the non-selective Gö6983 and Gö6976 compounds and a PKC ζ pseudo-substrate peptide containing a membrane-targeting myristoylation site (Roffey et al., Curr Opin Cell Biol, 21:268-279, 2009). The development of effective ATP-competitive inhibitors against aPKCs, similar to other protein kinases, has been complicated by challenges with both potency and selectivity. In general, such inhibitors acquire selectivity by associating with both the ATP-binding site and with adjacent residues, which are less well conserved. Other approaches include screening for allosteric inhibitors of PKC ζ that target the PIF pocket (Frohner et al., J Med Chem, 54:6714-6723, 2011; and Lopez-Garcia et al., Chem Biol, 18:1463-1473, 2011) or that block PKC ι interaction with Par-6 (Pillai et al., Int J Biochem Cell Biol, 43:784-794, 2011; Erdogran et al., J Biol Chem, 281:28450-18459, 2006; and Regala et al., Cancer Res, 68: 5888-5895, 2008). Recent studies have shown differential effects between PKC ζ and PKC ι for compounds targeting other aPKC-specific pockets outside of the ATP cleft. For instance, the use of CRT0066854 and its derivative compounds are predicted to be useful tools in further differentiating the roles of PKC ζ and PKC ι in establishing cell polarity and growth-factor-stimulated signaling pathways (Kjaer et al., Biochem J, 451:329-342, 2013).
PKC ζ plays an important role in the activation of TNF-alpha and NF-kB pathways, the latter of which are critical to the balance between host protection and pathology in malaria (Randall and Engwerda, Exp Parasitol, 126:326-331, 2010). In the context of malaria parasite biology, mammalian PKC activity has recently been shown to be critical for malaria parasite egress from infected red blood cells (Millholland et al., Cell Host Microbe, 13:15-28, 2013). Intriguingly, erythrocyte PKCs are comprised of cPKCα, as well as aPKC ζ and aPKC ι (Govekar and Zingde, Ann Hematol, 80:531-534, 2001). Thus during development of the present disclosure, aPKCs have been determined to be a primary target of PKC inhibitors that can reduce parasitemia. The effect on host RBC PKC activity is further substantiated by an examination of host versus parasite IC50s: the IC50 for PKC ζ is 60 nM (Gschwendt et al., FEBS Lett, 392:77-80. 1996), whereas the IC50 for the distantly (and only) related malaria parasite kinase PfPKB is >1000 nM (Kumar et al., J Biol Chem, 279:24255-24264, 2004). In the mosquito host, conserved PKC activity also controls parasite development: ingestion of PKC inhibitors, at levels consistent with those achievable in human blood, during feeding on an infected meal resulted in significantly reduced P. falciparum development in the mosquito Anopheles stephensi (Pakpour et al., PLoS One, 8(10): e76535, 2013). Further, expression of A. stephensi PKC ζ mRNA was significantly increased (5-fold) in the mosquito midgut upon blood feeding, a change that was consistent with PKC-dependent regulation of epithelial barrier permeability that likely controls resistance to parasite infection.
Effective inhibitor targeting of PKC activity in general and for aPKCs in particular is challenging. However, networked kinases, which interact as kinase and kinase substrate, may provide an opportunity for novel inhibitor design. In the mosquito, p38 MAPK inhibition significantly reduces malaria parasite development, observations confirmed with commercially available p38 MAPK inhibitors during development of the present disclosure (FIG. 3A-D). Prior to this work, the p38 MAPK inhibitor SB203580 was reported to reduce P. falciparum replication in human erythrocytes in vitro at concentrations exceeding 5 μM (Brumlik et al., Exp Parasitol, 128:170-175, 2011). However, no such effects of SB203580 up to 10 μM and no activity of a second p38 MAPK inhibitor BIRB 796 up to 10 μM against P. falciparum growth in vitro was observed (FIG. 2B). However, both inhibitors at 10 μM significantly reduced p38 MAPK activity in the mosquito in vivo when provided in the bloodmeal immediately prior to feeding, indicating that mosquito p38 MAPK activity controls parasite development (FIG. 2A). In mammalian cells, the PKC regulatory domain interacts directly with p38 MAPK kinase, which blocks PKC activity by preventing its autophosphorylation on T560 (but not on S113 or S186) and activation (Kim et al., Cell Death Differ, 12:201-212, 2005). Thus strategies to target p38 MAPK can be leveraged to enhance aPKC targeting. Specifically, in some embodiments, a PKC inhibitor (e.g., a molecule that is directed to the PKC PIF pocket) is used in combination with a p38 MAPK inhibitor to inhibit networked p38 MAPK and PKC ζ to enhance control of infection in the human host and transmission via the exposed mosquito. Of note, some p38 MAPK inhibitors have progressed into human clinical trials for not only cancer but also to inflammatory disease and cardiovascular disease with manageable side effects (Hammaker et al., Ann Rheum Dis, 69(S1):77-82, 2010).
In addition to inhibitors of aPKC and p38 MAPK, other kinase inhibitors, such as the JNK inhibitor SP600125 has been shown to reduce malaria disease severity, but without an effect on parasitemia (Anand et al., Parasitol Res, 112:1959-1966, 2013). However, during development of the present disclosure, inhibition of mosquito JNK activity was found to alter P. falciparum development in A. stephensi. Hence, in some embodiments, a JNK inhibitor in combination with a PKC inhibitor is used to reduce disease severity and parasitemia. Combinations of small molecule inhibitors (SMIs) of conserved kinases are provided as “next-generation” anti-malarials to control both disease severity and transmission, as well as to reduce risk of development of parasite drug resistance.
In some embodiments, SMIs of conserved signaling kinases are delivered as orally available therapeutics to malaria patients in endemic countries. The following list of SMI therapeutic attributes is applicable to both pediatric and adult patients: (1) single dose (or few dose) efficacy with inhibition of parasite growth and resolution of disease following treatment, (2) few to no contraindications and side effects, (3) long-term stability under conditions in endemic countries where refrigeration during storage and distribution are limited at best, (4) parasite transmission blocking activity in mosquitoes that feed on treated patients to counter potential “escape” of parasites from treated patients, (5) well-tolerated by the most sensitive populations, children and pregnant women as well as by G6PDH-deficient patients.
Structures of exemplary kinase inhibitors are shown in FIG. 1. Kinase inhibitors for use in the methods of the present disclosure include but are not limited to inhibitors of PKC, JNK, MAPK and other kinases, as well as salts and derivatives thereof. Exemplary PKC inhibitors include: bisindolylmaleimide IV (3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione); chelerythrine chloride (1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium; chloride); Go 6976 (5,6,7,13-Tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propa-nenitrile); Go 6983 (3-[1-[3-(dimethylamino)propyl]-5-methoxyindol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione); PKCβII/EGFR Inhibitor (5,6-bis(4-fluoroanilino)isoindole-1,3-dione); PKCβ Inhibitor (3-anilino-4-[1-(3-imidazol-1-ylpropyl)indol-3-yl]pyrrole-2,5-dione); N-benzoyl-staurosporine, staurosporine (Streptomyces sp.); bisindolylmaleimide III, hydrochloride (3-[1-(3-aminopropyl)indol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione; hydrochloride); Go 7874, hydrochloride; H-8, dihydrochloride (N-[2-(methylamino)ethyl]isoquinoline-5-sulfonamide; dihydrochloride); HA 1004, dihydrochloride (2-[2-(isoquinolin-5-ylsulfonylamino)ethyl]guanidine; dihydrochloride); UCN-01 (7-hydroxystaurosporine); and Ro-31-8220 (methanesulfonic acid; 3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate). Exemplary MAPK inhibitors include: p38 MAP Kinase Inhibitor IV (3,4,6-trichloro-2-(2,3,5-trichloro-6-hydroxyphenyl)sulfonylphenol); p38 MAP Kinase Inhibitor VI, JX401 ((4-benzylpiperidin-1-yl)-(2-methoxy-4-methylsulfanylphenyl)methanone); p38 MAP Kinase Inhibitor VII, SD-169 (1H-indole-5-carboxamide); p38 MAP Kinase Inhibitor VIII ([4-(2-amino-4-bromoanilino)-2-chlorophenyl]-(2-methylphenyl)methanone); BIRB 796 (1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea); SB203580 (4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine); SB 203580, Sulfone (4-[4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-1H-imidazol-5-yl]pyridine); and SB 239063 (4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol). Exemplary inhibitors of other kinases include: U0126 ((2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile); PD98059 (2-(2-amino-3-methoxyphenyl)chromen-4-one); and MEK1/2 Inhibitor II (N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-(4-iodo-2-methylanilino)benzamide).
Additional kinase inhibitors for use in the methods and compositions of the present disclosure are listed in Tables I-IV below.

TABLE I

Exemplary PKCepsilon Inhibitors

		PubChem	Parameter
Description	CAS No.	CID	(nM)

Staurosporine	62996-74-1	5279	IC₅₀= 0.08
Phorbol 12,13-dibutyrate	37558-16-0	37783	Kd = 0.81
SureCN2934634	N/A	45375865	IC₅₀= 1.6
GSK690693	937174-76-0	16725726	Kd = 5.3
Sotrastaurin	425637-18-9	10296883	IC₅₀= 6.2
Indolactam V	90365-57-4	105000	Ki = 7.7
Enzastaurin	170364-57-5	176167	Kd = 8.9
CHEMBL350335	N/A	9847089	IC₅₀= 10
Balanol analog 4	N/A	5327921	IC₅₀= 10
Ro-31-8220	138489-18-6	5083	IC₅₀= 10
Ruboxistaurin	169939-94-0	153999	Kd = 11
A674563	552325-73-2	11314340	Kd = 11
CHEMBL606245	N/A	44160269	IC₅₀= 14
Ro-32-0432	151342-35-7	127757	IC₅₀= 17.2
Ophiocordin	63590-19-2	5287736	IC₅₀= 20
Cediranib	288383-20-0	9933475	IC₅₀= 24
Bisindolylmaleimide I	133052-90-1	2396	IC₅₀< 25
K-252a	97161-97-2	3813	IC₅₀= 33
SureCN2934911	N/A	45375866	IC₅₀= 36
Ro-32-0557	N/A	19095896	IC₅₀= 48
PKCb Inhibitor	257879-35-9	6419755	IC₅₀> 50
Cdk1/2 Inhibitor III	443798-55-8	5330812	IC₅₀> 50
N-Benzoylstaurosporine	120685-11-2	56603681	IC₅₀= 50
Balanol analog 5	N/A	5327922	IC₅₀= 50
CHEMBL103055	N/A	10207821	IC₅₀= 75
AT9283	1092788-83-4	24905142	IC₅₀> 100
Bisindolylmaleimide XI, HCl	N/A	11605551	IC₅₀= 108
CHEMBL295806	N/A	44294447	IC₅₀= 120
SureCN5757856	N/A	10302405	IC₅₀= 140
SB218078	135897-06-2	447446	IC₅₀> 150
PKR Inhibitor	608512-97-6	6490494	IC₅₀> 150
Go6983	133053-19-7	3499	IC₅₀> 150
Lestaurtinib	111358-88-4	126565	Kd = 160
Bisindolylmaleimide IV	119139-23-0	2399	IC₅₀= 190
Y-27632	146986-50-7	448042	IC₅₀> 250
Arcyriaflavin A	118458-54-1	5327723	IC₅₀= 310
SureCN3774124	N/A	10209082	IC₅₀= 330
Alvocidib	131740-09-5	9910986	Kd = 380
BMS-690514	859853-30-8	11349170	Kd < 400
BCP9000906	457081-03-7	5494425	IC₅₀= 500
H-1152; Glycyl	913844-45-8	16760635	IC₅₀= 500
Ruxolitinib	941678-49-5	25126798	Kd = 530
SureCN2579964	N/A	24948986	IC₅₀< 750
PP121	1092788-83-4	24905142	IC₅₀< 750
SureCN2505235	N/A	5353854	IC₅₀= 1000
WZ3146	1214265-56-1	44607360	Kd > 1000
WZ4002	213269-23-8	44607530	Kd > 1000
Icotinib	610798-31-7	22024915	IC₅₀> 1000
MK5108	1010085-13-8	24748204	IC₅₀> 1000
JAK3 Inhibitor VI	856436-16-3	16760524	IC₅₀> 1000

TABLE II

Exemplary MAPK14 p38 Inhibitors

		PubChem	Parameter
Description	CAS No.	CID	(nM)

Doramapimod	285983-48-4	156422	Kd = 0.046
SPDD01923	N/A	447721	IC₅₀= 0.11
Kinome_3519	N/A	16730109	Ki = 0.2
SCIO-469	309913-83-5	9871074	Kd = 0.48
VX745	209410-46-8	3038525	IC₅₀= 0.8
CHEMBL420047	N/A	23646852	Kd = 1
CHEMBL383172	N/A	11235063	Ki = 1.6
SureCN4219451	N/A	9999342	IC₅₀= 1.8
SureCN5632345	N/A	44593646	Ki = 1.9
PH797804	586379-66-0	22049997	IC₅₀= 2.5
CHEMBL215652	N/A	23647319	IC₅₀= 2.5
AMG-47a	882663-88-9	16086114	IC₅₀= 3
SureCN4762364	N/A	10473563	IC₅₀= 3.2
VX702	745833-23-2	10341154	Kd = 3.7
SureCN3936664	N/A	11626920	IC₅₀= 5
Aminopyrimidine amide, 13b	N/A	16118737	IC₅₀= 5
2ofv	N/A	15991573	IC₅₀= 6
LY2228820	862507-23-1	11570805	IC₅₀= 7
CHEMBL213451	N/A	23647330	IC₅₀= 7.6
SureCN5495613	913376-83-7	24764449	IC₅₀= 9
SureCN6744546	N/A	24856363	Ki = 9
SureCN5774497	N/A	9948405	IC₅₀= 9.6
SB202190	152121-30-7	5353940	Kd = 9.8
SB203580	152121-47-6	176155	IC₅₀= 10
CHEMBL1964275	N/A	57394915	Kd < 10
SB220025	165806-53-1	5164	IC₅₀= 19
Dasatinib	302962-49-8	11153014	Kd = 27
p38 MAP Kinase Inhibitor	219138-24-6	4665	IC₅₀= 35
Sorafenib	284461-73-0	216239	IC₅₀= 38
CHEMBL1092754	N/A	44541014	IC₅₀= 50
PD169316	152121-53-4	4712	IC₅₀> 50
AST-487	630124-46-8	11409972	Kd = 73
A-83-01	909910-43-6	16218924	IC₅₀= 100
SB681323	444606-18-2	10297982	IC₅₀< 100
AT9283	1092788-83-4	24905142	IC₅₀> 100
Regorafenib	755037-03-7	11167602	IC₅₀< 100
7-hydroxystaurosporine	112953-11-4	72271	IC₅₀> 100
SKF-86002	72873-74-6	5228	IC₅₀= 110
Nilotinib	641571-10-0	644241	IC₅₀> 150
ZM336372	208260-29-1	5730	IC₅₀= 180
CHEMBL364623	302962-49-8	11153014	IC₅₀= 202
FR180204	865362-74-9	11493598	Ki = 310
Foretinib	849217-64-7	42642645	Kd = 320
ML3403	581098-48-8	6419739	IC₅₀= 380
SureCN4875304	N/A	46871765	IC₅₀= 540
AG1478	175178-82-2	2051	IC₅₀= 560
HG-9-91-01	N/A	N/A	IC₅₀< 600
LY364947	396129-53-6	447966	IC₅₀= 740
Celocoxib	194044-54-7	2662	IC₅₀= 810
BX517	N/A	11161844	IC₅₀> 900

TABLE III

Exemplary JNK1 Inhibitors

		PubChem
Description	CAS No.	CID	Parameter (nM)

Kinome_3027	N/A	11640926	Ki = 1 nM
JNK Inhibitor VIII	894804-07-0	11624601	Ki = 2 nM
Kinome_3024	N/A	11539329	Ki = 3 nM
Kinome_3028	N/A	11590363	Ki = 3 nM
Kinome_2553	N/A	16007116	Ki = 3.8 nM
Hesperadin	422513-13-1	10142586	Kd < 10 nM
Lestaurtinib	111358-88-4	126565	Kd = 11 nM
R406	841290-81-1	11984591	Kd = 38
JNKIN7	N/A	57340685	IC₅₀< 40 nM
JNKIN8	N/A	57340686	IC₅₀< 40 nM
TTT-3002	N/A	N/A	IC₅₀< 40 nM
1;9-Pyrazoloanthrone	129-56-6	8515	IC₅₀= 40 nM
7-hydroxystaurosporine	112953-11-4	72271	IC₅₀> 45 nM
Momelotinib	1056634-68-4	25062766	IC₅₀< 100 nM
Go6976	136194-77-9	3501	IC₅₀= 100 nM
AT9283	1092788-83-4	24905142	IC₅₀> 100 nM
Staurosporine aglycone	99533-80-9	3035817	IC₅₀< 100 nM
PP1 Analog II; 1NM-PP1	221244-14-0	5154691	IC₅₀= 140 nM
K-252a	97161-97-2	3813	IC₅₀> 150 nM
AS601245	345987-15-7	11422035	IC₅₀= 150 nM
CHEMBL1788116	N/A	11422034	IC₅₀= 150 nM
NVP-TAE684	761439-42-3	16038120	Kd = 160 nM
GSK1838705A	1116235-97-2	25182616	Kd = 210 nM
Staurosporine	62996-74-1	5279	Kd = 220 nM
TG101348	936091-26-8	16722836	Kd = 260 nM
Nilotinib	641571-10-0	644241	Kd = 450 nM
AST-487	630124-46-8	11409972	Kd = 460 nM
NU6140	444723-13-1	10202471	IC₅₀= 500 nM
KW2449	1000669-72-6	11427553	Kd = 580 nM
CZC-25146	330003-04-7	N/A	IC₅₀< 600 nM
Nintedanib	928326-83-4	9809715	Kd = 630 nM
KT5720	108068-98-0	3844	IC₅₀< 800 nM
BX517	N/A	11161844	IC₅₀> 900 nM
A 443654	552325-16-3	10172943	IC₅₀> 900 nM
Pyrrolo-pyrimidone; 17	N/A	16119021	IC₅₀= 960 nM
WZ3146	1214265-56-1	44607360	Kd > 1000 nM
WZ4002	213269-23-8	44607530	Kd > 1000 nM
MK5108	1010085-13-8	24748204	IC₅₀> 1000 nM
Silmitasertib	1009820-21-6	24748573	IC₅₀> 1000 nM
SNS314	N/A	16047143	IC₅₀> 1000 nM
K00596a	873225-46-8	9549298	IC₅₀= 100 nM
GSK-3 Inhibitor IX	667463-62-9	5287844	IC₅₀= 100 nM
Baricitinib	1187594-09-7	44205240	IC₅₀> 1000 nM
(5Z)-7-Oxozeaenol	66018-38-0	N/A	IC₅₀= 1000 nM
CP673451	343787-29-1	10158940	IC₅₀> 1000 nM
SureCN10063060	N/A	52936621	Ki > 1000 nM
SB203580	152121-47-6	176155	Kd = 1100 nM
SureCN5632345	N/A	44593646	Kd < 1250 nM
SureCN7018367	N/A	18792927	Kd < 1250 nM
IKK-2 Inhibitor IV	507475-17-4	9903786	Kd < 1250 nM

TABLE IV

Exemplary JNK3 Inhibitors

		PubChem
Description	CAS No.	CID	Parameter (nM)

Hesperadin	422513-13-1	10142586	Kd < 10 nM
SureCN7018367	312917-37-6	18792927	Kd < 10 nM
Lestaurtinib	111358-88-4	126565	Kd = 12 nM
Kinome_3027	N/A	11640926	Ki = 18 nM
1;9-Pyrazoloanthrone	129-56-6	8515	Kd = 22 nM
SB203580	152121-47-6	176155	Kd = 35 nM
JNKIN7	N/A	57340685	IC₅₀< 40 nM
JNKIN8	N/A	57340686	IC₅₀< 40 nM
SB202190	152121-30-7	5353940	Kd = 42 nM
KW2449	1000669-72-6	11427553	Kd = 51 nM
JNK Inhibitor VIII	894804-07-0	11624601	Ki = 52 nM
TTT-3002	N/A	N/A	IC₅₀< 60 nM
Doramapimod	285983-48-4	156422	Kd = 62 nM
NVP-TAE684	761439-42-3	16038120	Kd = 67 nM
AS601245	345987-15-7	11422035	IC₅₀= 70 nM
CHEMBL1788116	N/A	11422034	IC₅₀= 70 nM
AT9283	1092788-83-4	24905142	IC₅₀> 100 nM
Staurosporine aglycone	99533-80-9	3035817	IC₅₀< 100 nM
7-hydroxystaurosporine	112953-11-4	72271	IC₅₀> 100 nM
MK5108	1010085-13-8	24748204	IC₅₀> 100 nM
Staurosporine	62996-74-1	5279	Kd = 110 nM
Kinome_2553	N/A	16007116	IC₅₀= 120 nM
GSK1838705A	1116235-97-2	25182616	Kd = 130 nM
AMG-47a	882663-88-9	16086114	IC₅₀= 145 nM
JNK Inhibitor IX	312917-14-9	766949	IC₅₀= 200 nM
TG101348	936091-26-8	16722836	Kd = 200 nM
JNJ-28312141	885692-52-4	N/A	Kd = 240 nM
Nintedanib	928326-83-4	9809715	Kd = 270 nM
Go6976	136194-77-9	3501	IC₅₀> 300 nM
AC1NS4N8	N/A	23649240	Kd < 400 nM
Syk Inhibitor IV	732983-37-8	10200390	IC₅₀< 400 nM
PDK1/Akt/Flt Inhibitor	331253-86-2	5113385	IC₅₀= 500 nM
CZC-25146	330003-04-7	N/A	IC₅₀< 600 nM
R406	841290-81-1	11984591	IC₅₀< 600 nM
GSK650394A	890842-28-1	25022668	IC₅₀> 600 nM
Momelotinib	1056634-68-4	25062766	IC₅₀< 750 nM
AST-487	630124-46-8	11409972	Kd = 760 nM
VX702	745833-23-2	10341154	Kd = 780 nM
HG-9-91-01	N/A	N/A	IC₅₀< 800 nM
Ruboxistaurin	169939-94-0	153999	IC₅₀> 900 nM
GSK-3 Inhibitor IX	667463-62-9	5287844	IC₅₀> 900 nM
A 443654	552325-16-3	10172943	IC₅₀> 900 nM
HG-10-102-01	1351758-81-0	N/A	IC₅₀= 1000 nM
WZ3146	1214265-56-1	44607360	Kd > 1000 nM
WZ4002	213269-23-8	44607530	Kd > 1000 nM
Syk Inhibitor	622387-85-3	6419747	IC₅₀= 1000 nM
SGI-1776	N/A	N/A	IC₅₀> 1000 nM
Silmitasertib	1009820-21-6	24748573	IC₅₀> 1000 nM
SNS314	N/A	16047143	IC₅₀> 1000 nM
K00596a	873225-46-8	9549298	IC₅₀= 1000 nM

A therapeutically effective amount of a small molecule inhibitor (SMI), such as a protein kinase inhibitor, may vary depending upon the route of administration and dosage form. Effective amounts of SMIs typically fall in the range of about 0.0001 to 1000 mg/kg/day, typically 0.001 to 100 mg/kg/day, and more typically in the range of about 0.01 up to 10 mg/kg/day. In some embodiments, the SMI is administered to a subject in an amount less than any of the following daily doses (mg/kg): 100, 50, 10, 5.0, 1.0, 0.5 or 1. In some embodiments, the SMI is administered to a subject in an amount greater than any of the following daily doses (mg/kg): 0.001, 0.005, 0.01, 0.05, 0.1 or 0.5. That is, the daily dose (mg/kg) can be any of a range of having an upper limit of 100, 50, 10, 5.0, 1.0, 0.5 or 1, and an independently selected lower limit of 0.001, 0.005, 0.01, 0.05, 0.1 or 0.5, wherein the lower limit is less than the upper limit. Thus, the actual amount per day for an adult mammal weighing 70 kg is typically between 0.07 and 7,000 mg, or more typically between 0.7 and 700 mg, where this amount can be administered as a single dose per day or as a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same.
Typically, the SMI is selected to provide a formulation that exhibits a high therapeutic index. The therapeutic index is the dose ratio between toxic and therapeutic effects, which can be expressed as the ratio between LD₅₀and ED₅₀. The LD₅₀is the dose lethal to 50% of the population and the ED₅₀is the dose therapeutically effective in 50% of the population. The LD₅₀and ED₅₀are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
In some embodiments a SMI, such as a protein kinase inhibitor, is in the form of a pharmaceutically acceptable salt. For instance, when the SMI has a basic group, such as, for example, an amino group, pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., formic acid, acetic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid). Alternatively, when the SMI has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., sodium, lithium, potassium, calcium, magnesium, zinc), ammonia, organic amines (e.g., trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine), or basic amino acids (e.g., arginine, lysine and ornithine).
In a preferred embodiment, a SMI, such as a protein kinase inhibitor, is contained within a pharmaceutical composition. A preferred pharmaceutical composition is a single dosage form for oral administration, such as a tablet or capsule. A pharmaceutical composition in the form of a tablet suitable for oral administration can comprise one or more pharmaceutically acceptable carriers and/or excipients suitable (e.g., inactive ingredients). Exemplary carriers include but are not limited to lactose, cellulose (for example microcrystalline cellulose), and mannitol. Exemplary excipients include but are not limited to binding agents such as hydroxypropylmethylcellulose or povidone (polyvinylpyrollidone), lubricants such as magnesium stearate, and disintegrants such as sodium starch glycollate, croscarmellose sodium, or crospovidone (cross-linked polyvinylpyrollidone).
In some embodiments, kinase inhibitor formulations are comprised of at least two SMIs having high bioavailability (>20%) are administered to a population of parasite-infected patients. In the case of malaria, particularly preferred SMIs have an EC₅₀<10 nM in vitro and a single-digit mg/kg activity ED₉₀in a human erythrocyte-engrafted SCID mouse model. The kinase inhibitor formulations are either single-drug formulations comprising an SMI as the only active ingredient, or as a multi-drug formulation comprising a first SMI and a second SMI. The patient population is comprised of both children (over six months of age) and adults with confirmed and uncomplicated Plasmodium infection who are able to swallow oral medication. The patient pool does not exclude G6PD-deficient patients.
Patients receive the orally-available kinase formulations at an effective dose over the course of the study, during which the adequate clinical and parasitological response (ACPR) and the clinical parasite reduction ratio (PRR) are monitored. The study may range from 28 up to or over 48 days, with patients exhibiting a clinical efficacy at day 28 from a single dose (or a few doses) of the kinase formulation, measured as a PRR of over 50%.
The formulations described herein are also suitable for administration as prophylactic treatments in uninfected individuals traveling to a parasitic disease endemic area (e.g., malaria-endemic area).

Modified Kinase Inhibitors

Cell signaling connects immunity and basic intermediary metabolism at the mitochondrial level (Arnoult et al. EMBO REP 12:901-10, 2011). The links between mitochondria and host defense include modulation of bioenergetics by several protein kinases (PKs) (e.g., PKC, ERK, JNK, and p38 MAPK) (Horbinski and Chu, Free Radic Biol Med, 38:2-11, 2005) following PK activation/translocation to mitochondria in response to immune stimuli. As determined during development of the present disclosure, inhibition of mosquito p38 MAPK significantly reduces malaria parasite development. Without being bound by theory, the inhibition of parasite development is thought to be in response to p38 MAPK-regulated changes in mosquito midgut mitochondrial bioenergetics.
Some of the phosphorylation-dephosphorylation events that cells undergo when challenged with immune stimuli are not necessarily related to mitochondria-driven apoptosis, but to bioenergetics. These latter effects have been ascribed to the translocation and/or activation of critical PK within mitochondria. Thus, it would be advantageous to modify SMIs so as to redirect their localization to the mitochondrial compartment. The modified SMIs may result in less drug resistance, catabolism, and off-target effects relative to unmodified SMIs that localize to the cytosolic space (Mourtada et al., PLoS One, 8:e60253, 2013).
Suitable modifications to direct delivery of a SMI to a mitochondria include attachment of the SMI to a mitochondrial-targeting moiety, including but are not limited to lipophilic cations, mitochondrial-penetrating peptides, mitochondrial-targeting dyes, liposomes, and nanoparticles (see, e.g., Rin Jean et al., ACS Chem Biol, 9:323-333, 2014). Exemplary lipophilic cations include but are not limited to triphenylphosphonium (TPP)(Ross et al., Biochemistry, 70:222-230, 2005), AAI (Sun et al., Cancer Res, 54:1465-1471, 1994), and MKT-077 (Weisberg et al., Cancer Res, 56:551-555, 1996). Exemplary mitochondrial-penetrating peptides include but are not limited to SS-31 (Zhao et al., J Biol Chem, 279: 34682-34690, 2004), MPP (Horton et al., Chem Biol 15: 375-382, 2008), and those including 8-15 hydroxyl-containing (Serine, Threonine), positively charged amino acids (Arginine, Lysine) or hydrophobic natural and synthetic amino acids (phenylalanine, cyclohexylalanine)(Horton et al., Chem Biol, 15:375-82, 2008; and Yousif et al., Chembiochem, 10:1939-50, 2009).. Exemplary mitochondrial-targeting dyes include but are not limited to rhodamine and the dyes listed in Table V.

TABLE V

Mitochondrial Targeting Dyes

Dye	Description

4-Di-1-ASP (DASPMI)	4-(4-(Dimethylamino)-styryl)-N-methylpyridinium iodide
DASPEI	2-(4-(dimethylamino)styryl)-N-ethylpyridinium iodide
Dihydrorhodamine 123	Reduced form of Rhodamine 123
Dihydrorhodamine 123,	Reduced form of Rhodamine 123
dihydrochloride
JC-1 chloride	Membrane potential-dependent mitochondrial stain
JC-1 iodide	Membrane potential-dependent mitochondrial stain
MitoGreen	Green-fluorescent mitochondrial dye
MitoRed	Red-fluorescent mitochondrial dye
Nonyl Acridine Orange (NAO)	Membrane potential-independent mitochondrial stain
Rhodamine 123	Green-fluorescent mitochondria stain
Tetrabromorhodamine 123,	Green-fluorescent mitochondria stain
bromide
TMRE	Tetramethylrhodamine ethyl ester, perchlorate; membrane
	potential-sensitive dye
TMRM	Tetramethylrhodamine methyl ester, perchlorate; membrane
	potential-sensitive dye

Another strategy for modification of SMIs for use in the methods and compositions of the present disclosure involve the use of bifunctional inhibitors. These inhibitors tend to be more effective than those solely directed towards either the ATP binding site (Hu et al., Drug Discovery Today, 1:438-447, 1996) or the substrate-binding site (Lee et al., J Am Chem Soc, 126:3394-3395, 2004) because they are directed to both the ATP and substrate binding sites (Ricouart et al., J Med Chem, 34:73-78, 1991). The use of bisubstrate analog inhibitors has been described and applied to several kinases (Parang et al., Nature Structural Biology, 8:37-41, 2001; Parang and Cole, Pharmacology & Therapeutics, 93:145-157, 2002; Hines et al., Bioorganicchemistry, 33:285-297, 2005; Broom, J Med Chem, 32:2-7, 1989; and Lee et al., Chembiochem, 9:507-509, 2008), including PKCs (van Wandelen et al., ACS Chemical Biology, 8:1479-1487, 2013; van Ameijde et al., Organic & Biomolecular Chemistry, 8:1629-1639, 2010; and Poot et al., Chembiochem, 10:2042-2051, 2009), but never targeted specifically to mitochondria. A recent review cited lack of PKC isozyme selectivity and problematic delivery as reasons why, even after over 20 years of development, the full therapeutic potential of PKC has not yet been realized (Villalba and Altman, Current Cancer Drug Targets, 2:125-137, 2002). In some embodiments, bifunctional protein kinase inhibitors are targeted to mitochondria.

Combination Therapies

The present disclosure further provides methods for treating or preventing malaria comprising administering at least one kinase inhibitor and an additional antimalarial (e.g., a compound that is not a kinase inhibitor) to a subject in need thereof under conditions suitable for treating or preventing malaria. In some embodiments, the kinase inhibitor and the antimalarial are present in a single formulation, while in other embodiments the kinase inhibitor and the antimalarial are present in separate formulations. In some embodiments, the additional antimalarial comprises one or more compounds of the antimalarial classes selected from the group consisting of amino alcohols, aminoquinolines, antibiotics, antifolates, endoperoxides, sulfonamides, and others (see, e.g., Delves et al., PLoS Medicine, 9(2) e1001169, 2012).
In particular, the additional antimalarial compound(s) may be aminoquinolines (including, but not limited to, amodiaquine, naphthoquine, AQ-13, tert-butyl isoquine, hydroxycholoquine, pyronaridine, diethylprimaquine, bulaquine, primaquine, tafenoquine, piperaquine, NPC-1161B, and chloroquine), antibiotics (including, but not limited to, azithromycin, trimethoprim, trimethoprim-sulphamethoxazole, tetracycline, mirincamycin, doxycycline, thiostrepton, fosmidomycin, and clindamycin), endoperoxides (including, but not limited to, artemeter, artesunate, OZ439, OZ277, artemisinin, artemisone, and dihydroartemisinin), antifolates (such as pyrimethamine, proguanil, dapsone, cycloguanil, P218, and chlorproguanil), sulfonamides (such as sulfadoxine, sulfadiazine, and sulfmethoxazole), amino alcohols (such as lumefantrine, halofantrine, mefloquine, and quinine), or other antimalarial drugs (including, but not limited to, DSM1, DSM265, P218, BCX4945, synthetic peroxides, methylene blue, riboflavin, pentamidine, DHEA, cycloheximide, atovaquone, deferoxamine, and N-acetyl-D-penicillamine). In some embodiments, the combination therapy includes a fixed-dose artemisinin combination therapy. In some aspects, the artemisinin combination therapy is comprised of one or more kinase inhibitor as well as one or more of artemether, artesunate, dihydroartemisinin, artemisone, and artemisinin. In some embodiments, the additional antimalarial counteracts the malarial parasite at the same life stage(s) as the kinase inhibitor. In other embodiments, the additional antimalarial counteracts the malarial parasite at a different life stage from the kinase inhibitor.
The present disclosure also provides methods for treating or preventing other parasitic diseases comprising administering at least one kinase inhibitor and an additional antiparasitic agent (e.g., a compound that is not a kinase inhibitor) to a subject in need thereof under conditions suitable for treating or preventing the parasitic disease. In some embodiments, the kinase inhibitor and the antiparasitic agent are present in a single formulation, while in other embodiments the kinase inhibitor and the antiparasitic agent are present in separate formulations. In some embodiments, the parasitic disease is not malaria.
In some preferred embodiments, present disclosure provides methods for treating or preventing Chagas disease comprising administering at least one kinase inhibitor and an additional antiparasitic agent (e.g., a compound that is not a kinase inhibitor) to a subject in need thereof under conditions suitable for treating or preventing the parasitic disease. In some embodiments, the kinase inhibitor and the antiparasitic agent are present in a single formulation, while in other embodiments the kinase inhibitor and the antiparasitic agent are present in separate formulations. In some embodiments, the additional antiparasitic agent comprises an azole- or nitro-derivative, such as benznidazole, or nifurtimox.

Treatment of Infections by Other Protozoan Parasites

In other embodiments, the use of SMIs directed to mammalian kinase pathways is applied to diseases caused by other intracellular parasitic protozoa. A large number of protozoal pathogens spend a portion of their life cycle in a mammalian host, (e.g., human). Diseases caused by infection with other intracellular parasitic protozoa are also treated or prevented by mammalian kinase inhibitors. In particular, the present disclosure provides kinase inhibitors and methods for use thereof in mammalian subjects infected with a protozoan parasite selected from the group consisting of Giardia lamblia, Cryptosporidium parvum, Cyclospora cayetanensis, Entamoeba histolytica, Trichomonas tenax, Trichomonas hominis, Trichomonas vaginalis, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Toxoplasma gondii, Theileria lawrenci, and Theileria parva. In preferred embodiments, the protozoan parasite is vectored by an arthropod (e.g., sand fly-transmitted Leishmania, tick-borne Babesia microti, kissing bug-transmitted Trypanosoma cruzi, tsetse-transmitted Trypanosoma brucei), and the SMI is directed to mammalian and arthropod kinase pathways. In some embodiments, the disease is Chagas disease, caused by infection with Trypanosoma cruzi. In general, the present disclosure provides methods for use of kinase inhibitors in hosts infected with a protozoan parasite.

General Techniques

The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al., 1989); Oligonucleotide Synthesis (Gait, ed., 1984); Animal Cell Culture (Freshney, ed., 1987); Handbook of Experimental Immunology (Weir & Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (Miller & Calos, eds., 1987); Current Protocols in Molecular Biology (Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (Coligan et al., eds., 1991); The Immunoassay Handbook (Wild ed., Stockton Press NY, 1994); Bioconjugate Techniques (Hermanson, ed., Academic Press, 1996); and Methods of Immunological Analysis (Masseyeff, Albert, and Staines, eds., Weinheim: VCH Verlags gesellschaft mbH, 1993).

DEFINITIONS

As used herein, the singular form “a”, “an”, and “the” includes plural references unless indicated otherwise. For example, “an” excipient includes one or more excipients.
The phrase “comprising” as used herein is open-ended, indicating that such embodiments may include additional elements. In contrast, the phrase “consisting of” is closed, indicating that such embodiments do not include additional elements (except for trace impurities). The phrase “consisting essentially of” is partially closed, indicating that such embodiments may further comprise elements that do not materially change the basic characteristics of such embodiments. It is understood that aspects and embodiments described herein as “comprising” include “consisting” and/or “consisting essentially of” aspects and embodiments.
The terms “small molecule inhibitor” and “SMI” refer to an organic compound (e.g., JNK inhibitor SP600125) of low molecular weight (e.g., less than 900 Daltons, preferably less than 500 Daltons, unless bound to a mitochondrial-targeting moiety in which case the size could be >2 kDa but less than 5 kDa) that inhibits a biological process. Biopolymers such as nucleic acids, proteins, and polysaccharides of greater than 10 kDa are not small molecules, although the nucleotide, amino acid, and saccharide constituents are small molecules.
The term “mitochondrial-targeting moiety” refers to a functional group of a compound that directs the compound to the mitochondria or to a specific compartment therein. Examples of mitochondrial-targeting moieties include but are not limited to lipophilic cations, mitochondrial-penetrating peptides, mitochondrial-targeting dyes, liposomes and nanoparticles.
Administration a protein kinase inhibitor in combination with an additional protein kinase inhibitor or an additional anti-parasite drug includes simultaneous (concurrent) and consecutive administration in any order.
An “effective amount of” or “under conditions effective for” refers to administration of a protein kinase inhibitor in an amount sufficient to carry out a specifically stated purpose. An “effective amount” may be determined empirically and in a routine manner, in relation to the stated purpose.
The term “therapeutically effective amount” refers to an amount of an agent (e.g., protein kinase inhibitor) effective to “treat” a disease or disorder in a subject (e.g., a mammal such as a human). In the case of Chagas disease, the therapeutically effective amount of the agent reduces a sign or symptom of Chagas disease.
The terms “treating” or “treatment” of a disease refer to executing a protocol, which may include administering one or more drugs to an individual (human or otherwise), in an effort to alleviate signs or symptoms of the disease. Thus, “treating” or “treatment” does not require complete alleviation of signs or symptoms, does not require a cure, and specifically includes protocols that have a measurable effect on the individual.
As used herein, and as well-understood in the art, “treatment” is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
The terms “reduce” and “reduction” as used in reference to biological function (e.g., kinase activity, parasite development, etc.) refer to a measurable decrease in the function by preferably at least 50%, more preferably at least 75% and most preferably at least 90%. Depending upon the function, the reduction may be from 10-fold to 1,000,000-fold, or from 10, 100 or 1000-fold to 10,000, 100,000 or 1,000,000-fold.

EXAMPLES

Abbreviations: ACPR (adequate clinical and parasitological response); AMAS (amastigote); HTS (high throughput screen); JNK (c-Jun N-terminal kinase); MAPK (mitogen-activated protein kinase); PI3K (phosphoinositide 3-kinase); PKB (protein kinase B); PKC (protein kinase C); SMI (small molecule inhibitor); TRYP (trypomastigote).

Example 1

Screening Compounds for Effects on Cell Viability, Proliferation and Kinase Activity in Mosquito Cells In Vitro and In Vivo

Testing with immortalized Anopheles cells. Multiple cell lines created from minced mosquito embryos or larvae are available from Anopheles stephensi (ASE, MSQ43) and from Anopheles gambiae (4a3B, SUA). These cells are not derived from specific tissues, but rather were selected because they grew continuously under culture conditions after isolation. In general, these cells are phagocyte-like and immune-responsive, but cellular physiology is more muscle cell-like (Giulivi et al., Biochem J, 415:309-16, 2008). Small molecule inhibitors (SMIs) are analyzed using these cells first to establish concentration ranges that inhibit target protein kinases without toxic effects on mosquito cells.
Cell death assay. SMIs are diluted over a log-range for toxicity analyses. Assays against mosquito cells are performed in 96 well plates using CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega).
Cell doubling time assay. SMIs are diluted over a log-range to assay effects on mosquito cell doubling time (about 22 h). Assays are performed in 96 well plates using CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega).
In vitro kinase inhibition assays. HTSs (high-throughput screens) of candidate SMIs are performed against Anopheles sp. recombinant kinases (e.g., PKCs, JNK, and p38 MAPK). IMAP immobilized metal ion-affinity fluorescence polarization (Molecular Devices) is used to screen 10,000 kinase-focused collection compounds (Cancer Research Technology) at 30 μM. An exemplary HTS uses 10 pM of the kinase, 100 nM 5-FAM (fluorescein-amidite)-labeled peptide, and 30 μM ATP in a buffer consisting of 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM DTT and 0.25 mM EGTA as described (Kjaer et al., Biochem J, 451:329-342, 2013). SMIs with low IC₅₀(<2 μM) are further tested using the Millipore KinaseProfiler™ service (Millipore) or Kinomescan™ (Discoverx) to determine the selectivity of key compounds against a panel of kinases (human and predicted mosquito). A preferred SMI targets overlapping but diverse kinase-mediated pathways.
Cellular kinase inhibition assays. Conserved PKCs (Pakpour et al., PLoS One, PLoS ONE 8(10): e76535, 2013) and MAPKs control malaria parasite development in A. stephensi (ERK: Surachetpong et al. 2009 PLoS Pathog. 5(4):e1000366; p38 MAPK and JNK, unpublished data). The present disclosure is based on the understanding that SMIs against conserved kinases ingested in a blood meal containing malaria parasites from a treated human host will alter mosquito signaling to kill ingested parasites. SMI dilutions that are not toxic are assayed against mosquito cells in 96 well plates. Synthetic peptide targets (MARCKS peptide MO2-58 for cPKC, PKC-delta, PKC-epsilon; sc-3108 peptide for PKC-zeta; sc-3106 for PKC-mu or PKD) are used to distinguish effects of SMIs on PKC activity in Anopheles cells. Synthetic peptide targets (ERKtide, p38 substrate P03-58 or MK-2, and JNK substrate c-Jun) are used to distinguish effects of SMIs on MAPK activity in Anopheles cells. Briefly, cells are treated with SMIs, lysed and prepared for dot blot analysis of kinase activity analyses through detection of phosphorylation of appropriate substrates. GENBANK Accession Nos. of representative Anopheles gambiae kinase sequences are provided in Table 1-1.

TABLE 1-1

Mosquito Kinase Sequences

Kinase	Type	Accession No.

cPKC	conventional PKC	EAA0266.4
nPKC-delta	novel PKC	EDO64332.2
nPKC-epsilon	novel PKC	EAA07888.5
aPKC-zeta	atypical PKC	EAA00497.3
		EAA00702.3
PKD	protein kinase D	EAA06222.6
PKN	PKC-like	EAA03911.6
JNKa	c-Jun N terminal kinase	EAA03630.4
		GI: 157020897
JNKb	c-Jun N terminal kinase	EAA05905.3
		GI: 116131141
p38 MAPK	mitogen-activated protein kinase	EAA00194.4
		GI: 157013175

Example 2

Screening Compounds for Effects on Plasmodium Growth, Infectivity and Development in Erythrocytes, Mice and Mosquito Cells

Plasmodium growth and mammalian infection assays. In order to attribute SMI activity to effects on mosquito signaling proteins specifically, SMIs are routinely screened for growth effects on P. falciparum parasites maintained in human erythrocyte culture in vitro. Because parasites are ingested by mosquitoes in the formed of infected erythrocytes, testing SMIs against parasite-infected erythrocytes in vitro provides insight as to whether an SMI of interest affects only the mosquito host or affects both the mosquito host and malaria parasite biology. While SMI effects on the mosquito can all be beneficial in terms of transmission reduction, beneficial effects of SMIs for the malaria patient would necessarily depend on the demonstration of an effect of the SMI on parasite growth in erythrocytes.
P. falciparum growth assay. Aliquots of ring stage P. falciparum NF54 culture are synchronized using sorbitol 48 h prior to the assay and then plated in 96-well flat-bottom plates in complete RPMI 1640 with HEPES, hypoxanthine, and 10% heat-inactivated human serum. Parasites are treated with an SMI of interest or with an equivalent volume of dimethyl sulfoxide (DMSO) diluent for 50 h in a candle jar in a 37° C. incubator. The assays are terminated by replacing the culture medium with RPMI 1640 with 10% formaldehyde in PBS. Erythrocytes are stained with 10 μg of propidium iodide/ml in PBS for 1-2 h at room temperature. Infected RBCs are counted with a flow cytometer. The levels of parasite growth in response to treatment are normalized to DMSO controls, which are set to 100%. (see e.g., Pakpour et al., Infect Immun, 80:2141-9, 2012; and Drexler et al., J Exp Biol, 216:208-17, 2013). For SMIs or combinations of SMIs with an effect on parasite growth, analyses of target erythrocyte kinase(s) are completed (see, e.g., Millholland et al., Cell Host Microbe, 13:15-28, 2013).
Plasmodium yoelii yoelii 17XNL infection assay in mice. An established murine malaria model is used to assess effects of SMIs on P. y. yoelii in vivo (Luckhart et al., PLoS Pathog, 9(2):e1003180, 2013; and Chau et al., Infect Immun, 2013 Epub ahead of print). Parasitemias predictably follow a temporal rise that can reach high levels (10-15% infected of total erythrocytes) with significant detectable pathology to a variety of organs. With GFP-tagged P. y. yoelii 17XNL, parasite densities in mouse blood are analyzed using a fluorescence plate reader (96 well plate). Although GFP emission of parasites through live tissue and skin is low, parasite loads can be quantified as described in sampled blood from live mice and in the mouse body following infection with P. y. yoelii 17XNL labeled with GFP-luciferase (obtained from Dr. S. Kappe and described in Miller et al., PLoS ONE, 8(4): e60820, 2013). The bioluminescent signal in live mice infected with P. y. yoelii-GFP-luciferase blood stage parasites is intense in the spleen and the lungs, perhaps due to parasite sequestration in these tissues. Quantification of blood parasitemia using a fluorescence plate reader and of parasite burden in live mice using whole body imaging facilitates high throughput analyses of parasite infection over time using various doses of SMIs.
High throughput studies are initiated in the mouse model with IP injection of known SMI doses. To assess treatment, SMI formulations are administered daily by IP injection for 1-4 days to Plasmodium-infected mice. To assess prophylaxis, SMI formulations are administered daily by IP injection for 3-4 days to mice prior to Plasmodium infection. The effects of SMIs on parasitemia and disease severity over time is then assessed. If a SMI is bioactive against parasite infection, oral bioavailability is established. The same types of studies of are performed with orally delivered SMIs or control compounds to establish efficacy against infection and disease, as well as to determine pharmacokinetics in blood by high-performance chromatography and/or mass spectrometry of parent compounds.
Plasmodium growth and development in A. stephensi. A strain of P. falciparum that expresses GFP only in sexual stage parasites is used to monitor gametocyte ingestion and development within the first 24-32 hours following feeding by A. stephensi (Luckhart et al., PLoS Pathog, 9(2):e1003180, 2013). In a similar way, development of oocysts (3-12 days after infection) and sporozoites (12-16 days after infection) of GFP-tagged P. y. yoelii 17XNL is monitored in A. stephensi after feeding on infected mice. The presence of sporozoites is key to understanding risk of transmission, so detection of this stage is critical to monitor transmission-blocking efficacy of SMIs. Hence, high-throughput analyses can be performed to detect and quantify infection of A. stephensi with both P. falciparum and P. y. yoelii 17XNL. The ability to detect (i) P. falciparum infection following ingestion of SMI-treated parasite culture and (ii) following feeding on SMI-treated, parasite-infected mice provides key information on SMI transmission-blocking efficacy using the best models for human and mouse parasites currently available. Following high-throughput screening for SMIs that reduce transmission, quantitative analyses of gametocytogenesis in SMI-treated P. falciparum culture and in SMI-treated, infected mice is used to determine if transmission-blocking effects of SMIs are due to effects on sexual stage parasite development, to SMI effects on the mosquito host signaling kinases, or both. To understand SMI effects on the mosquito host, SMI action against conserved kinase targets in mosquito tissues is examined (see, e.g., Pakpour et al., Infect Immun, 80:2141-2149, 2012; and Surachetpong et al., PLoS Pathog. 5(4):e1000366, 2009).
Screening kinase inhibitor activity in A. stephensi. Addition of 10 μM SP600125 to a bloodmeal with P. falciparum notably decreased phosphorylation of JNK1/3 in the midgut of A. stephensi 3 hr after feeding relative to an identical untreated bloodmeal (FIG. 5). By comparison, provision of 1 μM SP600125 via bloodmeal resulted in a 15% reduction in midgut pJNK1/3 levels relative to controls, suggesting that relatively low levels of a JNK SMI are biologically active in A. stephensi.
When 1 μM or 10 μM SP600125 was provided to either A. freeborni or A. stephensi daily in water or once weekly via bloodmeal (with oviposition), no negative impact on lifespan was recorded for either mosquito species. In A. stephensi provided with a single dose of 10 μM SP600125 in a P. falciparum-infected bloodmeal, parasite infection prevalence in each of two cohorts (n=50), as well as infection intensity (mean oocysts in mosquitoes with at least one oocyst) was reduced (FIG. 6). The JNK inhibition of P. falciparum infection in A. stephensi was associated with enhanced expression of an array of immune genes in the mosquito midgut (FIG. 7).

Example 3

Administration of Kinase Inhibitor(s) to Human Patients to Treat Malaria

This example provides a description of a clinical study among malaria-infected individuals. The clinical and parasitological response (CPR) in test subjects receiving treatment with candidate kinase inhibitor(s) (test formulation) is compared to the CPR of control subjects receiving treatment with a control formulation (placebo or comparator).
Primary Objective: to compare the proportions of test and control subjects that are free of parasites in the blood at Day 28 post-treatment.
Secondary Objective(s): to compare the proportions of test and control subjects free of parasites in the blood at Day 7 post-treatment; to compare the time of clearance of fever in test and control subjects; and to compare the time to clearance of parasites in the blood in test and control subjects.
Tertiary Objective(s); compare the responses to treatment of test and control subjects according to the World Health Organization System (see WHO 2009 Methods for Surveillance of Antimalarial Drug Efficacy), described below.
Normal, Infected Subjects. This study is a subject- and observer-blinded, randomized, controlled study of malaria-infected, but otherwise healthy, adult and children subjects (ages 6 months to 55 years) to receive oral dosing with either the test formulation or the control formulation. Subjects are stratified by age, sex and pregnancy status (where applicable) prior to randomization.
G6PD Deficient Subjects. This study is a subject- and observer-blinded, randomized, controlled study of G6PD-deficient, malaria-infected adult and children subjects (ages 6 months to 55 years) to receive oral dosing with either the test formulation or the control formulation. Subjects are stratified by age, sex and pregnancy status (where applicable) prior to randomization.
Normal and G6PD-deficient subjects are divided into groups and receive either a once-daily or twice-daily dose, given on study Day 0. Subjects receiving either the once-daily or twice-daily dosing are further divided into groups receiving dosing on Day 0, Days 0-1, Days 0-2, Days 0-3, Days 0-4, Days 0-5, Days 0-6, or Days 0-7. All subjects are asked to return at Days 1, 2, 3, 7, 14, 21, 28 and 48 for clinical evaluation and parasitemia analysis.
Study Population. Subjects are selected from among malaria-infected male and female volunteers. Inclusion and exclusion criteria met by study participants are as follows. Inclusion Criteria: infection with Plasmodium (including P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi), ability to swallow oral medication, willingness to comply with the study protocol and ability to adhere to strict dosing requirements. Exclusion Criteria: clinically debilitating illness; signs or symptoms of severe or complicated malaria; and treatment with antimalarials within the previous 7 days.
WHO Classification of Responses to Treatment. For the purpose of this analysis, possible responses to treatment include early treatment failure, late clinical failure, late parasitological failure, and adequate clinical and parasitological response (ACPR) as described (see WHO 2009 Methods for Surveillance of Antimalarial Drug Efficacy). ACPR is defined as absence of parasitemia at Day 28, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure. Early treatment failure (ETF) includes patients exhibiting severe malaria between Days 1-3 in the presence of parasitemia, parasitemia on Day 2 higher than Day 0, parasitemia on Day 3 with a temperature of greater than or equal to 37.5° C., and parasitemia on Day 3 less than or equal to 25% of that on Day 0. Late clinical failure (LCF) includes patients not exhibiting ETF who have danger signs or severe malaria in the presence of parasitemia on any day between Day 4 and Day 28, and presence of parasitemia on any day between Day 4 and Day 28 with a temperature of greater than or equal to 37.5° C. Late parasitological failure (LPF) includes patients not exhibiting ETF or LCF who have parasitemia on any day between Day 7 and Day 28 in the absence of fever (less than 37.5° C.).
Preferred test formulations have a clinical efficacy (ACPR) on Day 7 of at least 90%, more preferably at least 95% and most preferably at least 99%. In some aspects, preferred test formulations have clinical efficacy (ACPR) of at least 50% on Day 28, more preferably at least 75% and most preferably at least 95%. Additional efficacy targets are described in Burrows et al., Malaria J, 12:187, 2013.
Statistical Analyses. All statistical tests comparing demographic, patient characteristic and safety data are conducted using the Kaplan-Meier method. ACPR is measured by blood smear or polymerase chain reaction.

Example 4

Administration of Kinase Inhibitor(s) to Human Subjects to Prevent Malaria

This example provides a description of a clinical study among healthy individuals traveling in malaria-endemic areas, which compares protection from malaria resulting from prophylactic treatment with candidate kinase inhibitor(s) (test formulation) to protection from malaria in control subjects receiving treatment with a control formulation (placebo or comparator).
Primary Objective: to compare the proportions of test and control subjects free of parasites in the blood at Day 28 post-treatment.
Secondary Objective(s): to compare the proportions of test and control subjects who have parasitemia in the absence of fever (less than 37.5° C.) at Day 28 post-treatment.
Normal, Non-infected Subjects. This study is a subject- and observer-blinded, randomized, controlled study of healthy adult and children subjects (ages 6 months to 55 years) at risk of contracting malaria by traveling to an endemic area to receive oral dosing with either the test formulation or the control formulation. Subjects are stratified by age, sex and pregnancy status (where applicable) prior to randomization.
G6PD Deficient Subjects. This study is a subject- and observer-blinded, randomized, controlled study of G6PD-deficient, but otherwise healthy, adult and children subjects (ages 6 months to 55 years) at risk of contracting malaria by traveling to an endemic area to receive oral dosing with either the test formulation or the control formulation. Subjects are stratified by age prior to randomization.
Subjects are divided into groups and receive either a once-daily or twice-daily dose, given on study Day 0 (1 or 2 days before entering the endemic area). All subjects are asked to obtain a parasitemia analysis and clinical evaluation at Day 28 post-treatment.
Study Population. Subjects are selected from among healthy male and female volunteers. Inclusion and exclusion criteria met by study participants are as follows. Inclusion Criteria: at risk of contracting malaria by traveling to a malaria endemic area, ability to swallow oral medication, willingness to comply with the study protocol and ability to adhere to strict dosing requirements, age over six months. Exclusion Criteria: clinically debilitating illness; signs or symptoms of severe or complicated malaria; and treatment with antimalarials within the previous 7 days.
Classification of Responses to Treatment. For the purpose of this analysis, possible responses to treatment include prophylaxis or treatment failure. Prophylaxis is defined as absence of parasitemia at Day 28 post-treatment. Treatment failure is defined as the presence of parasitemia at or before Day 28.
Preferred test formulations have a clinical efficacy (ACPR) of at least 50% on Day 28, more preferably at least 75% and most preferably at least 95%. Additional efficacy targets are described in Burrows et al., Malaria J, 12:187, 2013.
Statistical Analyses. All statistical tests comparing demographic, patient characteristic and safety data are conducted using the Kaplan-Meier method. Parasitemia is measured by blood smear or polymerase chain reaction.

Example 5

Screening Compounds for Effects on Trypanosoma Growth and Development In Vitro

Amastigote Growth Assay. SMIs are screened for growth effects on T. cruzi parasites maintained in Vero cells in vitro. Vero cells (1×10⁵/well) seeded on round coverslips into 24-well plates are infected with bloodstream T. cruzi trypomastigotes (TRYP). After 24 hours of parasite-host cell interaction (10:1 parasite:cell ratio), the infected cultures are washed to remove free parasites and incubated for another 72 hours with a test SMI (1 to 10 micromolar), a placebo, or control comparator. Cell cultures are set up in triplicate and maintained at 37° C. in 5% CO₂. Uninfected treated cultures exposed to vehicle (1% DMSO) are used as controls. The method for determining the rate of infection of host cells by T. cruzi has previously been described in detail (Nakajima-Shimada et al., Antimicrob Agents and Chemo, 40:2455-2458, 1996). Briefly, host cells attached to the coverslip seeded in 24-well plate are gently rinsed with phosphate-buffered saline, air-dried, fixed in absolute methanol and stained with Giemsa. The coverslip is then transferred to a glass slide where the mounted cells are finally observed under a light microscope. The percentage of host cells with more than one amastigote (AMAS) in the cytoplasm are counted and the mean number of AMAS per infected cell is determined by analyzing a total of 400 host cells distributed in randomly chosen microscopic fields.
Trypomastigote Growth Assay. Bloodstream TRYP are subjected to treatment by incubation of 1.5×10⁵TRYP with 1-10 micromolar of a test SMI, a placebo, or control comparator. Parasites are diluted in RPMI 1640 medium supplemented with 10% FCS, seeded in 96-well microplates, and incubated at 37° C. in a 5% CO₂atmosphere. After 24 hours, the remaining live parasites are counted in a Neubauer chamber as previously described (Fernandez et al., Experimental Parasitology, 124:172-180, 2010). Trypanocydal effect is determined by counting remaining TRYP at each concentration of drug with respect to a negative control group. Each assay is performed in triplicate.

Example 6

Screening Compounds for Effects on Trypanosoma Growth, Infectivity and Development in Mice

At least two T. cruzi strains are used for the infection assay: one lethal at the acute phase and the other non-lethal at the acute phase. Use of two strains in this matter facilitates evaluation of parasitemia reduction and cure in the acute and chronic phases of infection.

Parasitemia Reduction

Groups: N=5 (6 to 8 week old mice).
Infection: Lethal strain (100 blood TRYP) injected intradermally into the hind foot pad or alternatively or by intraperitoneal inoculation.
Treatment: SMI formulations are administered daily by IP injection for 5 days to Trypanosoma-infected mice, starting at parasitemia levels above 10⁴TRYP/ml of blood. Control formulations, a placebo or comparator, are tested in parallel to the SMI formulations. The effects of SMIs on parasitemia (e.g., twice weekly) and disease severity over time is then assessed. If a SMI is bioactive against parasite infection, oral bioavailability is established. The same types of studies are performed with orally delivered SMIs.

Cure at the Acute Phase

Groups: N=5 (6 to 8 week old mice).
Infection: Lethal strain (100 blood TRYP) injected intradermally into the hind footpad or alternatively by intraperitoneal inoculation.
Treatment: SMI formulations are administered daily by IP injection for 20 to 30 days to Trypanosoma-infected mice, starting at parasitemia levels above 10⁴TRYP/ml of blood. Control formulations, a placebo or comparator, are tested in parallel to the SMI formulations. The effects of SMIs on parasitemia and disease severity over time is then assessed. If a SMI is bioactive against parasite infection, oral bioavailability is established. The same types of studies are performed with orally delivered SMIs. PCR may also be employed to detect AMAS in mouse tissues.

Cure at the Chronic Phase.

Groups: N=5 (6 to 8 week old mice).
Infection: Non-lethal strain injected intradermally into the hind footpad or alternatively by intraperitoneal inoculation. In particular, a fluorescently-labeled non-lethal K98 strain may be used.
Treatment: SMI formulations are administered daily by IP injection for 30 days to Trypanosoma-infected mice, starting at parasitemia levels above 10⁴TRYP/ml of blood. Control formulations, a placebo or comparator, are tested in parallel to the SMI formulations. The effects of SMIs on parasitemia and disease severity over time is then assessed. If a SMI is bioactive against parasite infection, oral bioavailability is established. The same types of studies are performed with orally delivered SMIs. PCR may also be employed to detect AMAS in mouse tissues. If fluorescently labeled parasites of the non-lethal K98 strain are used, parasitemia measurements may be performed by microscopy or automated fluorescent cell counting.

Example 7

Administration of Kinase Inhibitor(s) to Human Patients to Treat Chagas Disease

This example provides a description of a clinical study among Trypanosoma cruzi-infected individuals. The clinical and parasitological response (CPR) in test subjects receiving treatment with candidate kinase inhibitor(s) (test formulation) is compared to the CPR of control subjects receiving treatment with a control formulation (placebo or comparator).
Primary Objective: to compare the proportions of test and control subjects that are free of parasites in the blood at 12 months post-treatment.
Secondary Objective(s): to compare the proportions of test and control subjects free of parasites in the blood at Weeks 8, 16, 24, and 40 post-treatment; to compare the safety and tolerability of the candidate kinase inhibitor(s) in test and control subjects; and to compare the time to clearance of parasites in the blood in test and control subjects.
Normal, Infected Subjects. This study is a subject- and observer-blinded, randomized, controlled study of Trypanosoma cruzi-infected, but otherwise healthy, adult subjects (ages 18 years and older) to receive oral dosing with either the test formulation or the control formulation. Subjects are stratified by age, sex and pregnancy status (where applicable) prior to randomization.
Study Population. Subjects are selected from among Trypanosoma cruzi-infected male and female volunteers. Inclusion and exclusion criteria met by study participants are as follows. Inclusion Criteria: infection with Trypanosoma cruzi, ability to swallow oral medication, willingness to comply with the study protocol and ability to adhere to strict dosing requirements. Exclusion Criteria: clinically debilitating illness; and signs or symptoms of severe or complicated Chagas disease.
Classification of Responses to Treatment. For the purpose of this analysis, a positive response to treatment (parasitological cure) is indicated by an absence of parasites in the blood, as measured by real time polymerase chain reaction.
Statistical Analyses. All statistical tests comparing demographic, patient characteristic and safety data are conducted using the Kaplan-Meier method. Parasitological cure is measured by real time polymerase chain reaction.

Claims

1. A method for treating or preventing Chagas disease comprising: administering a mammalian protein kinase inhibitor to a mammalian subject in need thereof under conditions effective for treating or preventing Chagas disease.

2. The method of claim 1, wherein the mammalian protein kinase inhibitor comprises a first kinase inhibitor and a second kinase inhibitor, and the administering reduces activity of a first mammalian protein kinase and a second mammalian protein kinase.

3. The method of claim 1, wherein the mammalian protein kinase comprises a member of a protein kinase C (PKC) family.

4. The method of claim 1, wherein the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a c-Jun N-terminal kinase (JNK) family, and a p38 mitogen activated protein kinase (MAPK) family.

5. The method of claim 1, wherein the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a protein kinase B (PKB) family, and a phosphoinositide 3-kinase (PI3K) family.

6. The method of claim 1, wherein the mammalian protein kinase inhibitor is capable of reducing activity of a Triatominae insect kinase.

7. The method of claim 1, further comprising administering an effective amount of a further mammalian enzyme inhibitor to the mammalian subject.

8. The method of claim 1, wherein the subject is infected with Trypanosoma cruzi.

9. The method of claim 8, wherein the subject is acutely infected with T. cruzi.

10. The method of claim 8, wherein the subject is chronically infected with T. cruzi.

11. The method of claim 8, wherein treating Chagas disease comprises alleviating a symptom of Chagas disease experienced by the subject.

12. The method of claim 11, further comprising administering an effective amount of an additional antiparasitic agent to the mammalian subject.

13. The method of claim 12, wherein the additional antiparasitic agent comprises one or both of benznidazole and nifurtimox.

14. The method of claim 1, wherein the subject is an uninfected individual planning to visit a Chagas disease endemic area after the administering step has commenced.

15. The method of claim 14, wherein preventing Chagas disease comprises protecting the subject from developing parasitemia during their visit to the endemic area for a period of up to thirty days.

16. A method of identifying an anti-Chagas disease compound, comprising:

(a) measuring activity of a mammalian or Triatominae insect protein kinase in the presence and absence of a test compound; and

(b) identifying the test compound as an anti-Chagas disease compound when the activity of the protein kinase is reduced in the presence as compared to the absence of the test compound.

17. The method of claim 16, further comprising growing insect cells in vitro in the presence and absence of the test compound and identifying the test compound as insect-cell safe when viability or doubling time of the insect cells is not significantly reduced in the presence as compared to the absence of the test compound.

18. The method of claim 16, wherein the mammalian protein kinase is a human protein kinase.

19. The method of claim 16, wherein the Triatominae insect protein kinase is a Rhodnius prolixus protein kinase.

20. (canceled)

21. (canceled)

22. A pharmaceutical composition comprising:

a protein kinase inhibitor attached to a mitochondrial-targeting moiety, and

one or both of a pharmaceutically acceptable excipient and carrier,

wherein the protein kinase inhibitor is present in an amount effective to treat or prevent Chagas disease in a mammalian subject.

23. A method for treating or preventing an arthropod-borne parasitic disease comprising: administering a mammalian protein kinase inhibitor to a mammalian subject in need thereof under conditions effective for treating or preventing the arthropod-borne parasitic disease, wherein the parasitic disease is not malaria.

24. The method of claim 23, wherein the mammalian protein kinase inhibitor comprises a first kinase inhibitor and a second kinase inhibitor, and the administering reduces activity of a first mammalian protein kinase and a second mammalian protein kinase.

25. The method of claim 23, wherein the mammalian protein kinase comprises a member of a protein kinase C (PKC) family.

26. The method of claim 23, wherein the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a c-Jun N-terminal kinase (JNK) family, and a p38 mitogen activated protein kinase (MAPK) family.

27. The method of claim 23, wherein the mammalian protein kinase comprises a member of one or more families selected from the group consisting of a protein kinase C (PKC) family, a protein kinase B (PKB) family, and a phosphoinositide 3-kinase (PI3K) family.

28. The method of claim 23, wherein the mammalian protein kinase inhibitor is capable of reducing activity of an arthropod kinase.

29. The method of claim 23, further comprising administering an effective amount of a further mammalian enzyme inhibitor to the mammalian subject.

30. The method of claim 23, wherein the subject is infected with an arthropod-borne parasite which is not a Plasmodium sp. parasite.

31. The method of claim 30, wherein the subject is acutely infected with the arthropod-borne parasite.

32. The method of claim 30, wherein the subject is chronically infected with the arthropod-borne parasite.

33. The method of claim 30, wherein treating the parasitic disease comprises alleviating a symptom of the parasitic disease experienced by the subject.

34. The method of claim 30, further comprising administering an effective amount of an additional antiparasitic agent to the mammalian subject.

35. The method of claim 23, wherein the subject is an uninfected individual planning to visit a parasitic disease endemic area, and the administering step commences before the visit.

36. The method of claim 35, wherein the subject is an uninfected individual planning to visit a parasitic disease endemic area, and the administering step concludes during or after the visit.

37. The method of claim 36, wherein preventing the parasitic disease comprises protecting the subject from developing parasitemia during their visit to the endemic area for a period of up to thirty days.

38. A method of identifying antiparasitic compound, comprising:

(a) measuring activity of a mammalian or insect protein kinase in the presence and absence of a test compound; and

(b) identifying the test compound as an antiparasitic compound when the activity of the protein kinase is reduced in the presence as compared to the absence of the test compound, and wherein the insect protein kinase is not a Anopheles sp. kinase.

39. The method of claim 38, further comprising growing insect cells in vitro in the presence and absence of the test compound and identifying the test compound as insect-cell safe when viability or doubling time of the insect cells is not significantly reduced in the presence as compared to the absence of the test compound, and wherein the insect cells are not Anopheles sp. cells.

40. The method of claim 38, wherein the mammalian protein kinase is a human protein kinase.

41. The method of claim 38, wherein the insect protein kinase is selected from the group consisting of a sand-fly protein kinase, a tick protein kinase and a tsetse fly protein kinase.

42. (canceled)

43. (canceled)

44. A pharmaceutical composition comprising:

a protein kinase inhibitor attached to a mitochondrial-targeting moiety, and

one or both of a pharmaceutically acceptable excipient and carrier,

wherein the protein kinase inhibitor is present in an amount effective to treat or prevent an arthropod-borne parasitic disease in a mammalian subject, wherein the parasitic disease is not malaria.

45. The pharmaceutical composition of claim 44, wherein the parasitic disease is selected from the group consisting of leishmaniasis, babesiosis, and African trypanosomiasis.